Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Raises €80 Million in Equity Placement

This article has been updated with additional information from Biocartis.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €80 million ($94.7 million) through a private placement via an accelerated bookbuild offering of 6.4 million new shares.

The firm said it sold the shares at an issue price of €12.50 each, and that the total 6.4 million shares represent approximately 14.3 percent of its outstanding shares.

Belgium-based Biocartis said it will use the net proceeds to fund expansions of its Idylla test menu, its sales and marketing activities, and its cartridge manufacturing capacity, as well as for working capital and other general corporate purposes.

JP Morgan, Degroof Petercam, KBC Securities, and Kempen acted as joint bookrunners.

When it announced the initiation of equity placement earlier today, Biocartis also said that Genomic Health planned to submit an order to the joint bookrunners for €4 million in connection to the recent collaboration announced between Biocartis and Genomic Health. The two firms announced in September that they plan to jointly develop an in vitro diagnostic version of Genomic Health's Oncotype DX breast cancer test on the Idylla platform, with the option to expand the collaboration to include additional tests in oncology and urology.

"The significant amount raised in today's private placement is an important milestone for Biocartis in securing funds for the further execution of its plans. We were pleased to see a bookbuilding process that combined solid demand from existing shareholders with strong interest from new local and international institutional investors wanting to invest." Biocartis CFO Ewoud Welten said in a statement. "We see the support expressed today by investors as a complement to our teams and partners, both working on making personalized medicine an everyday reality."

As a result of the issuance of new shares, the company said its share capital will increase to €510,697 from €446,697, and its issued and outstanding shares will increase to about 51.1 million ordinary shares from about 44.7 million ordinary shares.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.